Latest & greatest articles for ipratropium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ipratropium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ipratropium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ipratropium

21. Tiotropium: a potential replacement for ipratropium in patients with COPD

Tiotropium: a potential replacement for ipratropium in patients with COPD Tiotropium: a potential replacement for ipratropium in patients with COPD Tiotropium: a potential replacement for ipratropium in patients with COPD Shukla V K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shukla V K. Tiotropium: a potential replacement (...) for ipratropium in patients with COPD. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2002: 4 Authors' objectives To summarise the available evidence on tiotropium as a potential replacement for ipratropium in patients with chronic obstructive pulmonary disease. Authors' conclusions - Inhaled tiotropium provides a sustained bronchodilator effect over a 24-hour period in patients with chronic obstructive pulmonary disease (COPD). - There is some evidence that tiotropium 18g once

2002 Health Technology Assessment (HTA) Database.

22. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. (Abstract)

Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. Inhaled short acting beta2 adrenergic agonists and ipratropium bromide are both used in the treatment of acute exacerbations of chronic obstructive pulmonary disease.In patients with acute exacerbations of COPD to: 1. To assess the efficacy of short-acting beta-2 agonists against placebo; 2. Compare the efficacy of short-acting beta-2 agonists and ipratropium.A comprehensive (...) independently selected trials for inclusion. Differences were resolved by consensus. References listed in each included trial were searched for additional trial reports. Trials were combined using Review Manager using a fixed effects model. The size of the treatment effects were tested for heterogeneity.We identified no placebo-controlled comparisons of beta-2 agonists. Three studies permitted comparison of ipratropium to an inhaled beta-2 agonist. These studies included a total of 103 patients. The beta2

2001 Cochrane

23. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma

A meta-analysis of the effects of ipratropium bromide in adults with acute asthma A meta-analysis of the effects of ipratropium bromide in adults with acute asthma A meta-analysis of the effects of ipratropium bromide in adults with acute asthma Rodrigo G, Rodrigo C, Burschtin O Authors' objectives To determine whether inhaled ipratropium bromide provides additional benefits to adults with acute asthma, who are being treated with beta-agonists in an emergency department. Searching MEDLINE (...) was searched from 1978 to April 1999 using the following MeSH terms: 'N-isopropylatropine' or 'ipratropium bromide', and 'adult', 'acute asthma' or status asthmaticus'. Searches of Current Contents, the Science Citation Index, and review articles were also performed. Studies were limited to those published in the English language. Details of additional published and unpublished studies were obtained by contacting experts (pulmonologists and emergency physicians) and the manufacturer of ipratropium bromide

1999 DARE.

24. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD

Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Friedman M, Serby C W, Menjoge S S, Wilson J D, Hilleman D E, Witek T J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Pharmaceutical technology: ipratropium combined with albuterol in a single inhalational canister (Combivent; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA). Type of intervention Treatment. Economic

1999 NHS Economic Evaluation Database.

25. Nebulized ipratropium bromide in acute pediatric asthma: Does it reduce hospital admissions among children presenting to the emergency department?

Nebulized ipratropium bromide in acute pediatric asthma: Does it reduce hospital admissions among children presenting to the emergency department? Nebulized Ipratropium Bromide in Acute Pediatric Asthma: Does It Reduce Hospital Admissions Among Children Presenting to the Emergency Department? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page Access provided by Volume 34, Issue 1, Pages 75–85 Nebulized Ipratropium Bromide (...) BR, Kelly KD, Bota GW: Nebulized ipratropium bromide in acute pediatric asthma: Does it reduce hospital admissions among children presenting to the emergency department? Ann Emerg Med July 1999;34:75-85.] See related articles, p. 25 and p. 86. CLINICAL SCENARIO An 11-year old boy presents to the emergency department with shortness of breath and wheezing caused by acute asthma. He has a long history of asthma, usually exacerbated by a common cold. Three days before ED presentation, an upper

1999 Evidence-Based Emergency Medicine

26. Effect of nebulized ipratropium bromide on the hospitalization rates of children with asthma.

Effect of nebulized ipratropium bromide on the hospitalization rates of children with asthma. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1998 PedsCCM Evidence-Based Journal Club

27. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. (Abstract)

Effect of nebulized ipratropium on the hospitalization rates of children with asthma. Anticholinergic medications such as ipratropium improve the pulmonary function of patients with acute exacerbations of asthma, but their effect on hospitalization rates is uncertain.We conducted a randomized, double-blind, placebo-controlled study of 434 children (2 to 18 years old) who had acute exacerbations of moderate or severe asthma treated in the emergency department. All the children received (...) a nebulized solution of albuterol (2.5 or 5 mg per dose, depending on body weight) every 20 minutes for three doses and then as needed. A corticosteroid (2 mg of prednisone or prednisolone per kilogram of body weight) was given orally with the second dose of albuterol. Children in the treatment group received 500 microg (2.5 ml) of ipratropium bromide with the second and third doses of albuterol; children in the control group received 2.5 ml of normal saline at these times.Overall, the rate

1998 NEJM Controlled trial quality: predicted high

28. Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis

Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis Osmond M H, Klassen T P Authors' objectives To establish if ipratropium bromide, when given in conjunction with beta2-agonists, is beneficial to the health of children suffering with acute asthma. Searching MEDLINE was searched from 1966 to 1992 for articles published (...) , placebo-controlled trials were included. Specific interventions included in the review Inhaled ipratropium bromide and placebo in conjunction with inhaled beta2-agonists (fenoterol or salbutamol). Participants included in the review Children under 18 years who had an acute unprovoked asthma attack (by reasonable definition) were included. Outcomes assessed in the review Any of the following clinical or physiological outcomes were measured: change in vital signs, length of admission, peak expiratory

1995 DARE.

29. Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis

Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1995 PedsCCM Evidence-Based Journal Club

30. Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. (Abstract)

Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. 103 patients with acute airflow obstruction (56 asthma, 47 chronic obstructive pulmonary disease [COPD]) completed a double-blind trial of nebulised bronchodilator treatment in a hospital accident and emergency department. Each patient was randomised to receive either 10 mg of salbutamol nebuliser solution in 2 ml of saline or 10 mg of salbutamol in 2 ml (0.5 mg) of preservative-free ipratropium bromide (...) asthma the immediate PFR response to a mixture of salbutamol and ipratropium bromide was better than the response to nebulised salbutamol alone. For COPD patients, the two treatments were of equal benefit.

1989 Lancet Controlled trial quality: predicted high